Boyds

Boyds is a global drug development consultancy headquartered in Crewe, United Kingdom, with additional offices in Pennsylvania, Cambridge, and Dublin. Founded in 2005 by Professor Alan Boyd, the company provides specialist consultancy services to an international client base across the pharmaceutical, biotechnology, medical device, and academic sectors. Its work focuses on supporting the development of new, cutting-edge medicines for patient benefit. The firm brings together a wide range of drug development, clinical, medical, and regulatory expertise central to the development of pharmaceutical and biotechnology medicinal products and medical devices. Its team has deep experience across the full spectrum of drug development modalities, from small molecules and biologics to cell and gene therapies, spanning all therapeutic areas. Boyds partners with pharmaceutical companies, biotechs, spin-outs, and academic groups to accelerate development from concept to clinic and beyond. Boyds offers end-to-end drug development services, including regulatory affairs, clinical and medical affairs, clinical operations, product development, regulatory submission management, and regulatory and medical writing. Its award-winning Regulatory Affairs team has built long-standing, trusted relationships with multiple leading regulators including the FDA, EMA, and MHRA, founded on decades of experience and recognized for enabling productive, solution-focused discussions that move development forward. The company is renowned for its work in advanced and novel therapies, particularly cell and gene therapies, and also provides comprehensive regulatory support for small molecules and biologics. In 2018, Boyds was awarded the prestigious Queen's Award for Enterprise, International Trade, in recognition of its international work, and in particular its support in the development of gene therapies for the treatment of rare diseases. The company continues to operate as a private consultancy, supporting clients across the globe.

Boyds was founded in 2005 by Professor Alan Boyd. The company was established as a drug development consultancy focused on providing specialist services to the pharmaceutical and biotechnology industries. Over the years, it has grown into a global consultancy with offices in Pennsylvania, Cambridge, Crewe, and Dublin. In 2018, Boyds was awarded the prestigious Queen's Award for Enterprise, International Trade, in recognition of its international work, and in particular its support in the development of gene therapies for the treatment of rare diseases. This award highlighted the company's expertise in advanced therapies and its growing international footprint. The company has built a track record reflecting two decades of scientific expertise, regulatory insight, and trusted partnerships that help bring new medicines to patients. Its team has deep experience across the full spectrum of drug development modalities, from small molecules and biologics to cell and gene therapies, spanning all therapeutic areas. Boyds partners with pharmaceutical companies, biotechs, spin-outs, and academic groups to accelerate development from concept to clinic and beyond. Today, Boyds operates as a private consultancy, providing end-to-end drug development services including regulatory affairs, clinical and medical affairs, clinical operations, product development, regulatory submission management, and regulatory and medical writing. Its award-winning Regulatory Affairs team has built long-standing, trusted relationships with multiple leading regulators including the FDA, EMA, and MHRA.

• 2018

  Awarded the Queen's Award for Enterprise, International Trade.

• 2005

  Boyds founded by Professor Alan Boyd.

A global drug development consultancy providing specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines for patient benefit.

• Regulatory Affairs Consulting

  Facilitating the efficient development of medicinal products with the FDA, EMA, MHRA and global regulatory agencies.

• Clinical & Medical Affairs

  Experienced pharmaceutical physician support, strategic input and medical monitoring.

• Clinical Operations

  Comprehensive clinical trial monitoring and support from site feasibility and study start-up to closeout.

• Product Development

  Supporting strategic planning and tactical execution of development programs.

• Regulatory Submission Management

  Optimizing and streamlining the regulatory submission process.

• Regulatory and Medical Writing

  Expert medical and regulatory writers with broad therapeutic experience.

1. 1Regulatory Affairs & Drug Development Consulting | Boydsboydconsultants.com
2. 2Regulatory Affairs Consulting | Boydsboydconsultants.com
3. 3Drug Development Consulting Services | Boydsboydconsultants.com
4. 4About Boyds | Global Drug Development Consultancyboydconsultants.com
5. 5Boyds (United Kingdom) - Wikidatawikidata.org